Up to 80% of patients with diabetes mellitus develop lower urinary tract complications, most commonly diabetic bladder dysfunction (DBD). The aim of this study was to investigate the impact of diabetes on the function of the inner bladder lining (urothelium). Bladder compliance and intraluminal release of urothelial mediators, adenosine triphosphate (ATP) and acetylcholine (ACh) in response to distension were investigated in whole bladders isolated from 2-and 12-week streptozotocin (STZ)-diabetic rats. Intact and urothelium-denuded bladder strips were used to assess the influence of the urothelium on bladder contractility. Intraluminal ATP release was significantly enhanced at 2 weeks of diabetes, although not at 12 weeks. In contrast, intraluminal ACh release was unaltered by diabetes. Bladder compliance was also significantly enhanced at both 2 and 12 weeks of diabetes, with greatly reduced intravesical pressures in response to distension. Nerve-evoked contractions of bladder strips were significantly greater at 2 weeks of diabetes. When the urothelium was absent, nerve-evoked contractions were reduced, but contractions remained significantly elevated at lower frequencies of stimulation (<5 Hz) in diabetics. Interestingly, although relaxations of bladder strips to isoprenaline were unaltered by diabetes, removal of the urothelium unmasked significantly enhanced relaxations in strips from 2-and 12-week diabetic animals. In conclusion, diabetes alters urothelial function.
| INTRODUC TI ON
Lower urinary tract complications are among the most common and costly complications of diabetes mellitus, and have been estimated to affect up to 87% of patients with diabetes, 1 a rate greater than that of the widely known, and more widely researched complications, neuropathy and nephropathy. 2 In particular, approximately 50% of patients diagnosed with diabetes are affected by diabetic bladder dysfunction, 3 a condition characterized by a wide range of clinical symptoms, from problems with storage through to voiding symptoms. 4 Patients may have impaired voiding reflexes, that result in increased residual volumes at the end of urination, increased bladder capacity, decreased bladder sensation and decreased rates of contraction of the bladder wall. 5 Alternatively, diabetic bladder dysfunction can also present as overactive bladder, with distressing storage symptoms including urinary urgency, frequency, nocturia and incontinence. 3, 4 Thus, diabetic bladder dysfunction has a huge impact on patient quality of life and is a significant healthcare burden.
The pathogenesis of diabetic bladder dysfunction is not well understood. Studies have characterized both functional and structural changes within the bladder, including changes in bladder function and contractility, [6] [7] [8] [9] [10] [11] as well as alterations in bladder morphology, innervation and vasculature. 12, 13 These changes are temporal in nature, 6, 7 with the bladder undergoing a transition from a compensated state to a decompensated state with the duration and severity of diabetes. 6 However, alterations within the inner lining of the bladder, the urothelium, have been less well researched, particularly with relation to function.
The urothelium, while acting as a barrier to the urine, plays an essential role in signal transduction to the underlying nerves, smooth muscle and interstitial cells, influencing bladder function via the release of mediators including adenosine triphosphate (ATP) and acetylcholine (ACh) during bladder filling. 14 Diabetes has been shown to alter the bladder histologically, with progressive hypertrophy of the smooth muscle and urothelium over time. 10 Time-dependent breaches in the barrier structure of the urothelium, and upregulation of muscarinic and purinergic receptor expression, have also been reported. 15 This suggests that urothelial function may be altered in diabetes, although only a few studies have investigated this. These studies have demonstrated decreased release of prostaglandin E 2 (PGE 2 ) and F2α from isolated urothelial layers, 16 and increased ATP release along with depressed nitric oxide (NO) release in bladders from 4-week diabetic rats. 17 Urine PGE 2 has also been shown to be decreased in 12-week diabetic rats. 18 To date, there are no reports on the effects of diabetes on the release of the other key urothelial mediator, ACh. In addition, it is not clear whether alterations in ATP release vary with duration of diabetes. Thus, despite the growing evidence for the importance of the urothelium in bladder function, the impact of diabetes on urothelial function has not yet been fully elucidated. The aim of the study was to investigate urothelial mediator release from isolated whole bladders from streptozotocin-diabetic rats and the influence of the urothelium in modulating contractility of bladder strips.
| RE SULTS

| Effect of diabetes on animal parameters
Two-week diabetic animals lost body weight relative to age-matched controls (P < 0.01), while 12-week diabetic animals gained significantly less weight (P < 0.001) over the 12-week period compared to age-matched controls (Table 1) . Bladder weights were significantly greater than age-matched controls at both time points (Table 1) .
Blood glucose levels greater than 30 mmol/L were displayed on the glucometer as 'high', and all diabetic animals had blood glucose levels greater than 30 mmol/L (Table 1) .
| Effect of diabetes on bladder compliance
Isolated whole bladders were infused with saline to a volume of 1200 μL, which would normally increase intraluminal pressure close to the threshold required for initiation of voiding. Bladders from Mean (±SEM) bodyweight, change in bodyweight over the 2-or 12-wk period, bladder weight and blood glucose levels for 2-wk and 12-wk control and diabetic animals. **P < 0.01, ***P < 0.001 vs respective age-matched control, ## P < 0.01 vs 2-week controls, n = 8-11.
TA B L E 1 Animal parameters 2-week diabetic animals were significantly more compliant than control bladders, and intraluminal pressure did not rise above 10 mm Hg during the filling period. The intraluminal pressure recorded following distension was significantly reduced in bladders from 2-week diabetic animals (2.52 ± 0.15 mm Hg, P < 0.001) compared to controls (35.60 ± 7.20 mm Hg) ( Figure 1A ), and in 12-week diabetic animals compared to controls (3.50 ± 0.93 mm Hg vs 10.15 ± 0.83, P < 0.001) ( Figure 1B ).
| Effect of diabetes on intraluminal mediator release
Upon distension of whole bladders to a low volume (375 μL), intraluminal ATP release was below the level of quantification. However, ATP release following distension to a high volume (1200 μL) was significantly greater (P < 0.05) in bladders from 2-week diabetic animals compared to controls (Figure 2A ). At 12 weeks of diabetes, intraluminal ATP release was similar to controls ( Figure 2A ).
Intraluminal ACh was released following distension of bladders to both low and high volumes. Diabetes of 2 and 12 weeks duration did not alter ACh release ( Figure 2B ). ACh release was consistently less in samples collected following high-volume distensions compared to low-volume distensions ( Figure 2B ).
| Effects of diabetes on contractility of isolated bladder strips
Electrical field stimulation evoked efferent-nerve mediated contractions of bladder strips, which were completely abolished by tetrodotoxin (1 μmol/L) (data not shown). Nerve-evoked contractions were significantly greater in 2-week diabetic animals vs controls ( Figure 3A) ; however, there was no significant difference between 12-week diabetic and age-matched controls ( Figure 3B ). Upon removal of the urothelium, nerve-evoked contractions remained significantly elevated in strips from 2-week diabetics only at the lower frequencies (<5 Hz) ( Figure 3C ). This effect was also observed in strips from 12-week diabetic animals ( Figure 3D ). F I G U R E 1 Bladder compliance. Ex vivo pressure-volume relationships of isolated whole bladders from 2-wk (A) (n = 11) and 12-week (B) (n = 12) control and diabetic animals in response to distension, where bladders were filled at 150 μL/min. *P < 0.05, ** P < 0.01, ***P < 0.001 vs respective controls, Student's t test
Intraluminal adenosine triphosphate (ATP) and acetylcholine (ACh) release from whole bladders. Intraluminal ATP release following distension of isolated whole bladders with high volume (1200 μL) (A) and intraluminal ACh release following distension with low (375 μL) and high volume (B) from 2-wk and 12-wk control and diabetic animals (n = 5-7, *P < 0.05, ***P < 0.001, one-way analysis of variance with Tukey). Note that ATP release was not measurable following distension with low volume were similar in strips from 2-week controls and 2-week diabetics, respectively. In strips from 12-week controls and diabetics, maximum responses and potency of carbachol were also similar (1.16 ± 0.13 and 0.92 ± 0.17 mN/mg, pEC 50 6.28 ± 0.09 and 
| D ISCUSS I ON
The aim of the present study was specifically to investigate urothelial mediator release from isolated whole bladders, and the influence of the urothelium in modulating contractility of bladder 30 An alternative explanation may be that small amounts of ATP released at low-volume distensions are undetectable due to the activity of ecto-ATPase enzymes, which are known to be expressed within the urothelium.
31
Despite this complexity at low-volume bladder distensions, ATP release following high-volume distension was enhanced by diabetes of 2 weeks. Similarly, ATP release has been shown to be enhanced at 4 weeks of diabetes. 17 Thus, increased ATP release may be a feature of the early stages of diabetic bladder dysfunction. In other types of bladder dysfunction increased ATP release is thought to contribute to aberrant sensation and lead to altered bladder activity. 17, 32 In the present study, ATP release was not significantly greater at 12 weeks of diabetes compared to age-matched controls. This suggests a transition of urothelial function from a compensated state at 2 weeks to a decompensated state at 12 weeks, as demonstrated for a number of other parameters of bladder function in diabetes. 6, 7, 33 Alternatively, rather than a temporal change in ATP release with duration of diabetes, it may be that ATP metabolism is affected. While to our knowledge there have been no reports of altered ecto-ATPase activity within the bladder in diabetes, activity of these enzymes is altered in bladder tissues from patients with overactive bladder.
34
Regardless of the underlying mechanism, here we demonstrate temporal changes in intraluminal ATP in diabetic bladder dysfunction, which has not been previously reported.
The urothelium also synthesizes and releases the mediator ACh. 35 While less well understood than ATP, ACh may act on the underlying cell types, playing a role in bladder sensation and contraction.
14 ACh also acts in an autocrine and paracrine manner, to stimulate release of other mediators including NO and ATP. 14, 35 In the present study, ACh release was detected in intraluminal samples following both low-and high-volume distensions, although release was not affected by diabetes. ACh release was consistently lower following stretch to high-volume distension when compared to lowvolume distension. Non-neuronal ACh release from urothelial cells and human bladder strips increases with mechanical stretch, 35, 36 and so the most likely explanation for these findings is that during the longer filling time associated with the high-volume distension, ACh was broken down by endogenous acetylcholinesterases, known to be present in the bladder mucosa. 37 During bladder filling, the volume infused during high distension was sufficient to increase intraluminal pressure beyond 25 mm Hg in control animals, which is close to the threshold at which normal voiding would occur. 23 However, diabetes resulted in highly compliant bladders, in which pressure increased very little in response to the high-volume distension. This is consistent with previous in vivo cystometry studies, in which large increases in volume were needed for diabetic animals to sense a full bladder and to trigger micturition.
38
Other studies have also shown an increase in bladder weight, bladder capacity and in vivo compliance in diabetes. 12, 39 Interestingly, at 12 weeks there were also age-related changes in bladders from control animals, which showed similar high compliance with very little increase in pressure in response to the high-volume distension.
It is well known that bladders undergo remodelling with age, with a gradual loss of smooth muscle and increase in collagen, a larger filling capacity and functionally weaker smooth muscle and nerve-evoked contractions. 40 Hence, the change in compliance at 12 weeks of diabetes may not reflect a diabetes-induced pathological alteration.
Locally, the urothelium can influence contractility of the underlying smooth muscle, 41 for example via the release of a urotheliumderived inhibitory factor (UDIF), found in porcine and human bladders, [42] [43] [44] but as yet unidentified. Using urothelium-intact and denuded bladder strips we investigated whether diabetes alters this influence of the urothelium on bladder contractility. Diabetes did not affect contractile responses to the muscarinic receptor agonist carbachol, consistent with several previous studies, 45, 46 but in contrast to others showing depressed cholinergic contractions in 12-week diabetic bladder strips. 37 In addition, removal of the urothelium did not affect contractions in control strips. This confirms that UDIF, which inhibits contractile responses to carbachol in pig and human bladders, 42, 44 is not released from the rat bladder urothelium, as previously reported. 47 Relaxation responses of bladder strips to isoprenaline, a β-adrenoceptor agonist, were also unaltered by diabetes. However, removal of the urothelium unmasked greater relaxations in bladder strips from 2-week diabetic animals compared to denuded controls, and also enhanced relaxations in 12-week diabetic bladder strips relative to intact strips. These findings suggest that diabetes alters urothelium function in a complex manner. Both excitatory and inhibitory prostaglandins are released from the urothelium and are thought to influence detrusor activity, 48 and increased levels of prostaglandins are considered biomarkers for lower urinary tract dysfunction. 49 Release of PGE 2 , an excitatory prostaglandin, which would oppose relaxation, was found to be reduced in urothelial preparations from diabetic rats. 16 Thus, whether our findings can be Bladder distensions were performed by filling to either low volume (375 μL) or high volume (1200 μL). Following distension, the bladder was drained and intraluminal contents collected immediately on dry ice. These were stored at −30°C for later assay of the mediators ATP and ACh, as previously performed. 57 Intraluminal ATP was measured using an ATP determination kit (Molecular Probes, Invitrogen, Mount Waverley, VIC, Australia). This is a bioluminescence assay which determines ATP using luciferase and its substrate D-luciferin. The assay was performed according to the manufacturer's instructions, whereby a standard curve using known concentrations of ATP was constructed and used to determine ATP in the intraluminal samples.
Luminescence was measured using a microplate reader (Modulus, Promega, Turner Biosystems, Alexandria, NSW, Australia 
| Contractility of isolated bladder strips
| Statistical analysis
GraphPad Prism software (GraphPad, San Diego, CA, USA) was used to perform statistical analysis. For whole bladders, pressurevolume relationships were calculated, and data compared using unpaired two-way Student's t tests. Intraluminal mediator release from isolated whole bladder preparations was expressed as mean ± SEM of n experiments, where n was the number of bladders. Non-linear regression analysis of the concentration-response curves was used to determine the potency of the agonist (pEC 50 , the log of the concentration of a drug that produces half of the maximal response). Mean (±SEM) pEC 50 values and maximum responses were calculated, while mean frequency-response curves were determined for nerve-evoked contractions. For contractile data, n was the number of tissue strips. Data were normalized for tissue weight and compared using one-way analysis of variance with Tukey's post hoc test, or unpaired two-tailed Student's t test where appropriate, as indicated. P < 0.05 was considered statistically significant.
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